Gilead Sciences, Inc.
GILD · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.20 | 0.37 | -1.03 | 0.38 |
| FCF Yield | 3.13% | 0.52% | 1.18% | 2.45% |
| EV / EBITDA | 36.10 | 46.78 | 60.13 | 42.65 |
| Quality | ||||
| ROIC | 6.78% | 4.22% | 3.80% | 4.12% |
| Gross Margin | 79.80% | 78.80% | 76.90% | 79.11% |
| Cash Conversion Ratio | 1.35 | 0.42 | 1.34 | 1.67 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.02% | 1.77% | 2.04% | 1.77% |
| Free Cash Flow Growth | 499.86% | -56.44% | -41.55% | -32.15% |
| Safety | ||||
| Net Debt / EBITDA | -1.80 | 5.87 | 6.54 | 5.57 |
| Interest Coverage | 13.00 | 9.74 | 8.60 | 9.85 |
| Efficiency | ||||
| Inventory Turnover | 0.36 | 0.82 | 0.88 | 0.92 |
| Cash Conversion Cycle | 310.67 | 135.30 | 118.96 | 102.48 |